CoChat
Sign Up
Cited by 30NF-κB Signaling PathwaysLiver physiology and pathologySignaling Pathways in Disease

Noncanonical NF-κB Signaling Pathway in Liver Diseases

Open access
Chen, Qianhui, Lu, Xinyu, Zhang, Xiaoyong·2020·Journal of Clinical and Translational Hepatology
DOI 10.14218/jcth.2020.00063PMC PMC7868705
Open this paper in CoChat — free accountOpen PDF

Abstract

The noncanonical NF-κB signaling pathway is an important branch of NF-κB signaling. It is involved in regulating multiple important biological processes, including inflammation and host immune response. A central adaptor protein of the noncanonical NF-κB pathway is NF-κB-inducing kinase (NIK), which activates the downstream kinase IKKα to process p100 to p52, thereby forming the RelB/p52 heterodimer to initiate the expression of target genes. Currently, many specific inhibitors and monoclonal antibodies targeting or triggering this pathway are being developed and tested for various diseases, including cancers, autoimmune diseases, and virus infection. Given that aberrant activation of the noncanonical NF-κB pathway is frequently observed in various liver diseases, targeting this pathway may be a promising therapeutic strategy to alleviate liver inflammation. Moreover, activation of this pathway may contribute to the antiviral immune response and promote the clearance of persistent hepatotropic virus infection. Here, we review the role of the noncanonical NF-κB pathway in the occurrence and development of different liver diseases, and discuss the potency and application of modulating the noncanonical NF-κB pathway for treatment of these liver diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14218/jcth.2020.00063

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Excessive activation of Wnt/β-catenin and TGF-β during liver regeneration can disrupt the balance of the cell cycle and contribute to the formation of tumor cells.

    “However, some studies indicate that excessive activation of Wnt/β-catenin and TGF-β during LR can disrupt the balance of the cell cycle and contribute to the formation of tumor cells.”

    From Liver regeneration after partial hepatectomy: Triggers and mechanisms (2025) · cites this paper as [50]

    The liver-regeneration section discusses noncanonical NF-κB signaling and hepatocyte proliferation, while the viral-associated hepatocellular carcinoma section discusses tumor formation in a different signaling context. Searches for Wnt/β-catenin, TGF-β, and cell-cycle disruption found no passage linking their excessive activation during liver regeneration to tumor-cell formation. The indexed passages have no page numbers. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. [1]Hoesel B Schmid JA The complexity of NF-κB signaling in inflammation and cancer Mol Cancer 2013 12 86 10.1186/1476-4598-12-86 23915189 PMC3750319 · DOI
  2. [2]Mulero MC Huxford T Ghosh G NF-κB, IκB, and IKK: Integral components of immune system signaling Adv Exp Med Biol 2019 1172 207 226 10.1007/978-981-13-9367-9_10 31628658 · DOI
  3. [3]Meyerovich K Ortis F Cardozo AK The non-canonical NF-κB pathway and its contribution to β-cell failure in diabetes J Mol Endocrinol 2018 61 F1 F6 10.1530/JME-16-0183 29728424 · DOI
  4. [4]Sun SC The non-canonical NF-κB pathway in immunity and inflammation Nat Rev Immunol 2017 17 545 558 10.1038/nri.2017.52 28580957 PMC5753586 · DOI
  5. [5]Sun SC Non-canonical NF-κB signaling pathway Cell Res 2011 21 71 85 10.1038/cr.2010.177 21173796 PMC3193406 · DOI
  6. [6]Tilborghs S Corthouts J Verhoeven Y Arias D Rolfo C Trinh XB The role of Nuclear Factor-kappa B signaling in human cervical cancer Crit Rev Oncol Hematol 2017 120 141 150 10.1016/j.critrevonc.2017.11.001 29198328 · DOI
  7. [7]Mitchell S Vargas J Hoffmann A Signaling via the NFκB system Wiley Interdiscip Rev Syst Biol Med 2016 8 227 241 10.1002/wsbm.1331 26990581 PMC8363188 · DOI
  8. [8]Dejardin E Droin NM Delhase M Haas E Cao Y Makris C The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways Immunity 2002 17 525 535 10.1016/s1074-7613(02)00423-5 12387745 · DOI
  9. [9]Claudio E Brown K Park S Wang H Siebenlist U BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells Nat Immunol 2002 3 958 965 10.1038/ni842 12352969 · DOI
  10. [10]Gardam S Brink R Non-canonical NF-κB signaling initiated by BAFF influences B cell biology at multiple junctures Front Immunol 2014 4 509 10.3389/fimmu.2013.00509 24432023 PMC3880999 · DOI
  11. [11]Boyce BF Xiu Y Li J Xing L Yao Z NF-κB-mediated regulation of osteoclastogenesis Endocrinol Metab (Seoul) 2015 30 35 44 10.3803/EnM.2015.30.1.35 25827455 PMC4384681 · DOI
  12. [12]Armstrong CL Galisteo R Brown SA Winkles JA TWEAK activation of the non-canonical NF-κB signaling pathway differentially regulates melanoma and prostate cancer cell invasion Oncotarget 2016 7 81474 81492 10.18632/oncotarget.13034 27821799 PMC5348407 · DOI
  13. [13]Xiao X Balasubramanian S Liu W Chu X Wang H Taparowsky EJ OX40 signaling favors the induction of T(H)9 cells and airway inflammation Nat Immunol 2012 13 981 990 10.1038/ni.2390 22842344 PMC3806044 · DOI
  14. [14]Zhang Q Lenardo MJ Baltimore D 30 years of NF-κB: A blossoming of relevance to human pathobiology Cell 2017 168 37 57 10.1016/j.cell.2016.12.012 28086098 PMC5268070 · DOI
  15. [16]Zarnegar BJ Wang Y Mahoney DJ Dempsey PW Cheung HH He J Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK Nat Immunol 2008 9 1371 1378 10.1038/ni.1676 18997794 PMC2676931 · DOI
  16. [17]Sun SC The noncanonical NF-κB pathway Immunol Rev 2012 246 125 140 10.1111/j.1600-065X.2011.01088.x 22435551 PMC3313452 · DOI
  17. [18]Vallabhapurapu S Matsuzawa A Zhang W Tseng PH Keats JJ Wang H Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling Nat Immunol 2008 9 1364 1370 10.1038/ni.1678 18997792 PMC2671996 · DOI
  18. [19]He JQ Zarnegar B Oganesyan G Saha SK Yamazaki S Doyle SE Rescue of TRAF3-null mice by p100 NF-kappa B deficiency J Exp Med 2006 203 2413 2418 10.1084/jem.20061166 17015635 PMC2118128 · DOI
  19. [20]Xie P Stunz LL Larison KD Yang B Bishop GA Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs Immunity 2007 27 253 267 10.1016/j.immuni.2007.07.012 17723217 PMC2084086 · DOI
  20. [21]Gardam S Sierro F Basten A Mackay F Brink R TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor Immunity 2008 28 391 401 10.1016/j.immuni.2008.01.009 18313334 · DOI
  21. [22]Xiao G Fong A Sun SC Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation J Biol Chem 2004 279 30099 30105 10.1074/jbc.M401428200 15140882 · DOI
  22. [23]Razani B Zarnegar B Ytterberg AJ Shiba T Dempsey PW Ware CF Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation Sci Signal 2010 3 ra41 10.1126/scisignal.2000778 20501937 PMC2913610 · DOI
  23. [25]Allen IC Wilson JE Schneider M Lich JD Roberts RA Arthur JC NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling Immunity 2012 36 742 754 10.1016/j.immuni.2012.03.012 22503542 PMC3658309 · DOI
  24. [26]Lich JD Williams KL Moore CB Arthur JC Davis BK Taxman DJ Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes J Immunol 2007 178 1256 1260 10.4049/jimmunol.178.3.1256 17237370 · DOI
  25. [27]Hu WH Mo XM Walters WM Brambilla R Bethea JR TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation J Biol Chem 2004 279 35975 35983 10.1074/jbc.M405699200 15208311 · DOI
  26. [28]Li T Morgan MJ Choksi S Zhang Y Kim YS Liu ZG MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation Nat Immunol 2010 11 799 805 10.1038/ni.1918 20711193 PMC2926307 · DOI
  27. [29]Shen H Sheng L Xiong Y Kim YH Jiang L Chen Z Thymic NF-κB-inducing kinase regulates CD4+ T cell-elicited liver injury and fibrosis in mice J Hepatol 2017 67 100 109 10.1016/j.jhep.2017.02.025 28267623 PMC5476485 · DOI
  28. [30]Shen H Ji Y Xiong Y Kim H Zhong X Jin MG Medullary thymic epithelial NF-kB-inducing kinase (NIK)/IKKα pathway shapes autoimmunity and liver and lung homeostasis in mice Proc Natl Acad Sci U S A 2019 116 19090 19097 10.1073/pnas.1901056116 31481626 PMC6754592 · DOI
  29. [31]Shen H Sheng L Chen Z Jiang L Su H Yin L Mouse hepatocyte overexpression of NF-κB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis Hepatology 2014 60 2065 2076 10.1002/hep.27348 25088600 PMC4245385 · DOI
  30. [32]Kawasaki K Abe M Tada F Tokumoto Y Chen S Miyake T Blockade of B-cell-activating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity Lab Invest 2013 93 311 321 10.1038/labinvest.2012.176 23318884 · DOI
  31. [33]Hadinia A Doustimotlagh AH Goodarzi HR Arya A Jafarinia M Plasma levels and gene expression of RANK in non-alcoholic fatty liver disease Clin Lab 2020 66 10.7754/Clin.Lab.2019.190913 32390378 · DOI
  32. [34]Sun G Jin H Zhang C Meng H Zhao X Wei D OX40 regulates both innate and adaptive immunity and promotes nonalcoholic steatohepatitis Cell Rep 2018 25 3786 3799.e4 10.1016/j.celrep.2018.12.006 30590049 · DOI
  33. [35]Sheng L Zhou Y Chen Z Ren D Cho KW Jiang L NF-κB–inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action Nat Med 2012 18 943 949 10.1038/nm.2756 22581287 PMC3766969 · DOI
  34. [36]Liu Y Sheng L Xiong Y Shen H Liu Y Rui L Liver NF-κB-inducing kinase promotes liver steatosis and glucose counterregulation in male mice with obesity Endocrinology 2017 158 1207 1216 10.1210/en.2016-1582 28379340 PMC5460833 · DOI
  35. [37]Jiang B Shen H Chen Z Yin L Zan L Rui L Carboxyl terminus of HSC70-interacting protein (CHIP) down-regulates NF-κB-inducing kinase (NIK) and suppresses NIK-induced liver injury J Biol Chem 2015 290 11704 11714 10.1074/jbc.M114.635086 25792747 PMC4416871 · DOI
  36. [38]Ren X Li X Jia L Chen D Hou H Rui L A small-molecule inhibitor of NF-κB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury FASEB J 2017 31 711 718 10.1096/fj.201600840R 27871061 · DOI
  37. [39]Karaca G Xie G Moylan C Swiderska-Syn M Guy CD Krüger L Role of Fn14 in acute alcoholic steatohepatitis in mice Am J Physiol Gastrointest Liver Physiol 2015 308 G325 G334 10.1152/ajpgi.00429.2013 25524063 PMC4329478 · DOI
  38. [40]Li Y Chen M Zhou Y Tang C Zhang W Zhong Y NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease Theranostics 2020 10 3579 3593 10.7150/thno.40149 32206109 PMC7069072 · DOI
  39. [41]Zhang C Jin H Wang Y Li C Zhao X Li Y Critical role of OX40 in drug-induced acute liver injury Br J Pharmacol 2020 177 3183 3196 10.1111/bph.15041 32133635 PMC7312313 · DOI
  40. [42]Yue S Xue N Li H Huang B Chen Z Wang X Hepatoprotective effect of apigenin against liver injury via the non-canonical NF-κB pathway in vivo and in vitro Inflammation 2020 43 1634 1648 10.1007/s10753-020-01238-5 32458347 · DOI
  41. [43]Elßner C Goeppert B Longerich T Scherr AL Stindt J Nanduri LK Nuclear translocation of RELB is increased in diseased human liver and promotes ductular reaction and biliary fibrosis in mice Gastroenterology 2019 156 1190 1205.e14 10.1053/j.gastro.2018.11.018 30445013 · DOI
  42. [44]Zhang B Hu M Zhang P Cao H Wang Y Wang Z BAFF promotes regulatory T-cell apoptosis and blocks cytokine production by activating B cells in primary biliary cirrhosis Braz J Med Biol Res 2013 46 433 439 10.1590/1414-431X20132665 23681290 PMC3854395 · DOI
  43. [45]Chen Y Sun R Wu X Cheng M Wei H Tian Z CD4+CD25+ regulatory T cells inhibit natural killer cell hepatocytotoxicity of hepatitis B virus transgenic mice via membrane-bound TGF-β and OX40 J Innate Immun 2016 8 30 42 10.1159/000431150 26067079 PMC6738770 · DOI
  44. [46]Publicover J Gaggar A Jespersen JM Halac U Johnson AJ Goodsell A An OX40/OX40L interaction directs successful immunity to hepatitis B virus Sci Transl Med 2018 10 eaah5766 10.1126/scitranslmed.aah5766 29563320 PMC6018058 · DOI
  45. [47]Ryu HM Park SG Yea SS Jang WH Yang YI Jung G Gene expression analysis of primary normal human hepatocytes infected with human hepatitis B virus World J Gastroenterol 2006 12 4986 4995 10.3748/wjg.v12.i31.4986 16937494 PMC4087401 · DOI
  46. [48]Lucifora J Xia Y Reisinger F Zhang K Stadler D Cheng X Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA Science 2014 343 1221 1228 10.1126/science.1243462 24557838 PMC6309542 · DOI
  47. [49]Schoggins JW Wilson SJ Panis M Murphy MY Jones CT Bieniasz P A diverse range of gene products are effectors of the type I interferon antiviral response Nature 2011 472 481 485 10.1038/nature09907 21478870 PMC3409588 · DOI
  48. [50]Lowey B Hertz L Chiu S Valdez K Li Q Liang TJ Hepatitis C virus infection induces hepatic expression of NF-κB-inducing kinase and lipogenesis by downregulating miR-122 mBio 2019 10 e01617 e01619 10.1128/mBio.01617-19 31363036 PMC6667626 · DOI
  49. [51]Haybaeck J Zeller N Wolf MJ Weber A Wagner U Kurrer MO A lymphotoxin-driven pathway to hepatocellular carcinoma Cancer Cell 2009 16 295 308 10.1016/j.ccr.2009.08.021 19800575 PMC4422166 · DOI
  50. [52]Khlaiphuengsin A Chuaypen N Sodsai P Buranapraditkun S Boonpiyathad T Hirankarn N Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma World J Gastroenterol 2020 26 2645 2656 10.3748/wjg.v26.i20.2645 32523317 PMC7265148 · DOI
  51. [53]Fei X Zhang P Pan Y Liu Y MicroRNA-98-5p inhibits tumorigenesis of hepatitis B virus-related hepatocellular carcinoma by targeting NF-κB-inducing kinase Yonsei Med J 2020 61 460 470 10.3349/ymj.2020.61.6.460 32469170 PMC7256008 · DOI
  52. [54]Chung C Park SG Park YM Joh JW Jung G Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation Cancer Sci 2007 98 1758 1766 10.1111/j.1349-7006.2007.00591.x 17711513 PMC11159465 · DOI
  53. [55]Cho HA Park IS Kim TW Oh YK Yang KS Kim JS Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes Arch Pharm Res 2009 32 1077 1086 10.1007/s12272-009-1714-z 19641890 · DOI
  54. [56]Anders RA Subudhi SK Wang J Pfeffer K Fu YX Contribution of the lymphotoxin beta receptor to liver regeneration J Immunol 2005 175 1295 1300 10.4049/jimmunol.175.2.1295 16002734 · DOI
  55. [57]Chou CH Ho CM Lai SL Chen CN Wu YM Shun CT B-cell activating factor enhances hepatocyte-driven angiogenesis via B-cell CLL/lymphoma 10/nuclear factor-kappab signaling during liver regeneration Int J Mol Sci 2019 20 5022 10.3390/ijms20205022 PMC6829427 31658764 · DOI
  56. [58]Karaca G Swiderska-Syn M Xie G Syn WK Krüger L Machado MV TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice PLoS One 2014 9 e83987 10.1371/journal.pone.0083987 24416188 PMC3886973 · DOI
  57. [59]Xiong Y Torsoni AS Wu F Shen H Liu Y Zhong X Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases Elife 2018 7 e34152 10.7554/eLife.34152 30070632 PMC6078493 · DOI
  58. [60]Puri P Sanyal AJ The BAFFling problem of B cell-activating factor in nonalcoholic fatty liver disease Hepatol Int 2013 7 309 312 10.1007/s12072-012-9418-8 26201767 PMC4871813 · DOI
  59. [61]Li Z Li X Su MB Gao LX Zhou YB Yuan B Discovery of a potent and selective NF-κB-inducing kinase (NIK) inhibitor that has anti-inflammatory effects in vitro and in vivo J Med Chem 2020 63 4388 4407 10.1021/acs.jmedchem.0c00396 32216342 · DOI
  60. [62]Yang C Li N Wang Y Zhang P Zhu Q Li F Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases J Interferon Cytokine Res 2014 34 787 794 10.1089/jir.2014.0032 24811691 PMC4186800 · DOI
  61. [63]Liu D Wu A Cui L Hao R Wang Y He J Hepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90β PLoS One 2014 9 e91658 10.1371/journal.pone.0091658 24618592 PMC3950214 · DOI
  62. [64]Ebert G Allison C Preston S Cooney J Toe JG Stutz MD Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis Proc Natl Acad Sci U S A 2015 112 5803 5808 10.1073/pnas.1502400112 25902530 PMC4426438 · DOI
  63. [65]Ebert G Preston S Allison C Cooney J Toe JG Stutz MD Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus Proc Natl Acad Sci U S A 2015 112 5797 5802 10.1073/pnas.1502390112 25902529 PMC4426461 · DOI
  64. [66]Stohl W Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE) Expert Rev Clin Immunol 2017 13 623 633 10.1080/1744666X.2017.1291343 28164726 · DOI
  65. [67]Ramadass V Vaiyapuri T Tergaonkar V Small molecule NF-κB pathway inhibitors in clinic Int J Mol Sci 2020 21 5164 10.3390/ijms21145164 PMC7404026 32708302 · DOI

Cited by

Sorted by citations

Authors
Chen, Q., Lu, X., & Zhang, X.
Affiliations
Nanfang Hospital (CN)
Corresponding author
Zhang, Xiaoyong
ORCID
Venue
Journal of Clinical and Translational Hepatology
Publisher
Xia & He Publishing
Published
2020-12-21
Volume
000
Issue
000
Pages
1-9
ISSN
  • 2225-0719 (ISSN-L)
  • 2310-8819
DOI
10.14218/jcth.2020.00063
PMC
PMC7868705
OpenAlex
W3114563145
Cited by
30
References
2
Citations by year
2026: 3 · 2025: 8 · 2024: 9 · 2023: 5 · 2022: 2 · 2021: 3
FWCI
0.25
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Journal of Clinical and Translational Hepatology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (2018ZX10301202, 81871664)
  • National Science and Technology Major Project (2018ZX10301202)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
non-canonical NF-κB signaling, NIK, IKKα, p100 processing, liver disease, liver inflammation, antiviral immunity, therapeutic targeting, monoclonal antibodies, small molecule inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review